This is an established, EU-GMP-certified pharmaceutical cannabis company in Portugal with a state-of-the-art indoor cultivation facility. The company is looking for a strategic equity partner to invest €5.5 million at a €12.8 million pre-money valuation to support their next phase of expansion.
Business Highlights:
Facility & Operations
- 5,000 m² GACP/EU-GMP-certified indoor facility features multiple GACP cultivation rooms, EU-GMP-compliant post-harvest areas, and an R&D lab.
- Have been in operation since 2020, achieving GMP certification in 2023 with a current production capacity of 2,000 KG per year (expandable to 10,000 KG per year).
- Facility is equipped with solar panels that deliver up to 35% electricity savings, making it sustainable and cost efficient.
Market Position & Revenue Potential
- Secured multi-year supply contracts that are projected to generate over €30 million in revenue.
- Existing distribution agreements across Germany, Poland, Portugal, Switzerland, and Australia, with an active expansion into the UK market.
- Phase 1 production capacity is fully allocated, driving the need for immediate expansion.
Growth & Expansion Potential
- Approved expansion plan for scaling production to 10,000 KG per year, with permits secured for facility extension.
- Potential to leverage an affiliated facility that offers additional production capacity for a strategic partner.
- A strategic development plan that includes acquiring a European distributor, with revenue projections that exceed €50 million annually.
Investment Opportunity:
Get situated with a pharma cannabis company with deep industry expertise, access to EU and U.S. licensed facilities, and leadership from Big Pharma executives. This is the ideal opportunity for investors who want strong market positioning, high-revenue potential, and a growing opportunity in the medical cannabis sector.
Become a strategic equity partner and help accelerate this company’s success in Europe.
